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Abstract
Background: The study was conducted to evaluate the 
analytical and clinical performance of the VIDAS® 25-OH 
Vitamin D Total assay. The clinical performance of the 
assay was compared with four other immunoassays 
against the results of two different liquid chromatography/
mass spectrometry methods (LC-MS/MS)  standardized to 
NIST reference materials.
Methods: VIDAS® 25-OH Vitamin D Total assay precision, 
linearity, detection limits and sample matrix comparison 
were assessed following CLSI guidelines. For method 
comparison, a total of 150 serum samples ranging from 7 
to 92 ng/mL were analyzed by all the methods. Correlation 
was studied using Passing-Bablok regression and Bland-
Altman analysis. The concordance correlation coefficient 
(CCC) was calculated to evaluate agreement between 
immunoassays and the reference LC-MS/MS method. In 
addition, samples containing endogenous 25(OH)D2 were 
used to assess each immunoassay’s ability to detect this 
analyte. Pregnancy and hemodialysis samples were used 
to the study the effect of vitamin D binding protein (DBP) 
concentration over VIDAS® assay performance.
Results: The VIDAS® 25-OH Vitamin D Total assay 
showed excellent correlation to the LC-MS/MS results 
(y = 1.01x+0.22 ng/mL, r = 0.93), as obtained from two dif-
ferent sites and distinct LC-MS/MS methods. The limit of 
quantification was determined at 8.1 ng/mL. Cross-reac-
tivity for 25(OH)D2 was over 80%. At concentrations of 
10.5, 26 and 65.1 ng/mL, within-run CVs were 7.9%, 3.6% 
and 1.7%, while total CVs (between runs, calibrations, lots 
and instruments) were 16.0%, 4.5% and 2.8%. The VIDAS® 
performance was not influenced by altered DBP levels, 
though under-recovery of 25(OH)D as compared to LC-MS/
MS was observed for hemodialysis samples.
Conclusions: The VIDAS® 25-OH Vitamin D Total assay is 
therefore considered suitable for assessment of vitamin D 
status in clinical routine.
Keywords: assay performance; liquid chromatography/
mass spectrometry; standardization; 25-OH vitamin D.
Introduction
Vitamin D is a fat-soluble steroid pro-hormone that plays 
a pivotal role in bone metabolism and calcium homeosta-
sis. In this context, vitamin D deficiency is associated with 
rickets, osteoporosis and secondary hyperparathyroidism 
[1–3]. Moreover, non-skeletal functions of vitamin D have 
been extensively discussed in recent studies [4–6]. Vitamin 
D insufficiency is considered an important risk factor in 
diabetes, cardiovascular diseases, autoimmune disorders 
and various forms of cancer [7]. Vitamin D is found in two 
forms: vitamin D3 (cholecalciferol) synthesized by action 
of solar ultraviolet radiation on the skin and found in 
food (oily fish); vitamin D2 (ergocalciferol) of exogenous 
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origin only (food or medical  supplementation). Vitamin 
D is first converted in the liver to 25-hydroxy vitamin D 
[25(OH)D] and then to its active form 1,25-dihydroxyvita-
min D [1,25(OH)D] in the kidneys [8]. 25(OH)D is found in 
nanomolar concentrations in serum or plasma and has 
a half-life of several weeks. This makes 25[OH]D the pre-
ferred analyte and the most relevant clinical indicator for 
the determination and monitoring of vitamin D status, 
provided the measurement method quantitates equally 
the 25(OH)D2 and 25(OH)D3 forms. Indeed, due to the lipo-
philic nature of vitamin D and its strong binding capabil-
ity to vitamin D binding protein (DBP) or human serum 
albumin, equal quantitation of both 25(OH)D forms is a 
technical challenge. However, this is not the only hurdle 
in designing an immunoassay that achieves the level of 
analytical performance required by clinical laboratories. 
State-of-the-art immunoassays have shown discrepancies 
in terms of accuracy, precision, linearity and correlation 
to liquid chromatography-mass spectrometry/mass spec-
trometry (LC-MS/MS), which has become a true reference 
method due to efforts to harmonize results driven by the 
use of international standards [9, 10]. Recently, publica-
tions have pointed out the influence of assay design with 
regards to technical features [11] and the necessity to use 
methodologies that adequately challenge the assay design 
to establish analytical performance. In this context, a new 
VIDAS® 25-OH Vitamin D Total immunoassay that meas-
ures both 25(OH)D2 and 25(OH)D3 has been developed. 
The purpose of this multicentric study was to evaluate 
the technical and clinical performance of the VIDAS® 
25-OH  Vitamin D Total assay and to compare it to two 
LC-MS/MS methods and four vitamin D immunoassays 
which are commercially available.
Materials and methods
Description of the VIDAS® 25-OH Vitamin D Total assay
The study concentrated on the performance of the VIDAS® 25-OH 
Vitamin D Total assay. This method is a sequential competitive 
immunoassay. All of the assay steps are performed automatically 
by the instrument. The Solid Phase Receptacle (SPR®) serves as the 
solid phase as well as the pipetting device for the assay. The sam-
ple is mixed with pre-treatment reagent to separate 25(OH)D from 
its binding protein. The pre-treated sample is then collected and 
transferred into the well that contains an alkaline phosphatase 
(ALP)-labeled anti-vitamin D antibody (conjugate). The vitamin D 
antigen present in the sample and the vitamin D antigen coating the 
interior of the SPR compete for binding sites on the anti-vitamin D 
antibody-ALP conjugate. During the final detection step, the sub-
strate (4-methylumbelliferyl phosphate) is cycled in and out of the 
SPR. The conjugate enzyme catalyzes the hydrolysis of this substrate 
into a fluorescent product (4-methylumbelliferone), the fluorescence 
of which is measured at 450 nm. The intensity of the fluorescence 
is inversely proportional to the concentration of vitamin D antigen 
present in the sample. Results are automatically calculated by the 
instrument in relation to the calibration curve. The VIDAS® 25-OH 
Vitamin D Total assay is standardized to internal controls that are 
traceable to a LC-MS/MS method calibrated with NIST SRM972a.
Analytical methods
VIDAS® 25-OH Vitamin D Total assay specificity was assessed 
through determination of cross-reactivity for vitamin D structural 
analogs according to CLSI protocol CLSI EP7-A2 [12]. Two samples at 
25(OH)D levels of 20 and 40 ng/mL were spiked with various con-
centrations (10–100 ng/mL) of vitamin D3, 1,25(OH)2D3, 24,25(OH)2D3 
and 3-epi-25(OH)D3, then samples were tested in triplicate with three 
reagent lots. Mean cross-reactivity for each analyte is calculated as 
XR% = ([25(OH)D measured in interfering pool] – [25(OH)D measured 
in non-spiked pool])/(spiked concentration of interfering material).
Assay precision was determined across the dynamic range using 
assay controls and serum samples according to a modified version 
from CLSI protocol EP05-A2 [13]. Two replicates of each sample were 
tested twice per day in separate runs, for 5 days, on three reagent lots 
and two different VIDAS® instruments (bioMérieux, Marcy l’Etoile, 
France). Variance components that pertain to each studied variation 
source were estimated by performing a nested-design variance analy-
sis. Variability is expressed in standard deviation (SD) and percent 
coefficient of variation (CV).
Assay linearity was evaluated using two serum pools, one high 
concentration sample and one low concentration sample, both at 
25(OH)D levels close to the limits of the VIDAS® assay calibration 
range. High and low samples were sequentially mixed to generate 12 
samples of intermediate concentrations. Each sample was tested in 
duplicate with three reagent lots. To determine linearity, the polyno-
mial analysis method was used as described in CLSI protocol EP6-A 
[14], with a deviation from linearity  < 12% over the entire measuring 
range.
The limit of blank (LoB) and the limit of detection (LoD) were 
determined according to CLSI protocol EP17-A2 [15]. LoB corresponds 
to the highest measurement result that is likely to be observed for a 
blank sample with a stated probability of 5%. Four blank samples 
(SeraCon™ Vitamin D Depleted Diluent, Seracare) were tested in 
duplicate for 8 days, on three reagent lots. LoB corresponds to the 
95th percentile of the blank sample distribution and is calculated 
non-parametrically. LoD corresponds to a measured quantity value 
for which the probability of falsely claiming the absence of the 
analyte is  < β = 5%, given a probability α = 5% of falsely claiming its 
presence. Nine low-level samples were tested five times per day, for 
8 days, on three reagent lots. A precision profile equation was gener-
ated and LoD was determined taking into account LoB. Limit of quan-
tification (LoQ) – or functional sensitivity – corresponds to the lowest 
amount of 25(OH)D that can be quantitatively determined with stated 
accuracy of CV < 20% and is calculated using the precision profile 
equation.
The serum and plasma equivalence comparison was car-
ried out using whole blood from 60 volunteer study participants 
(who gave their informed consent under the supervision of the 
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Ethics Committee) collected into serum-collection plastic tubes 
( Becton-Dickinson ref. 369032) and plasma-collection lithium hep-
arin plastic tubes ( Becton-Dickinson ref. 368884). Samples were 
processed according to the tube manufacturer’s recommendations. 
Matched serum and plasma samples were tested in singulate within 
the same assay run.
Samples
Serum samples (n = 150) for method comparison were selected based 
on their 25(OH)D concentration determined by LC-MS/MS. These were 
residual laboratory samples, blinded to patient identification and 
information. The sample cohort spans the measuring range of the assay 
methods (6–100 ng/mL) with approximately half of the specimens 
within the clinical decision range (15–40 ng/mL). No detectable levels 
of 25(OH)D2 ( > 2 ng/mL) were found in the 150 samples of this cohort. 
To determine 25(OH)D2 cross reactivity, another panel of 20 serum 
samples from vitamin D2-fortified volunteers was used exclusively. 
As determined by LC-MS/MS, 25(OH)D2 levels ranged from 15.5 to 68.5 
ng/mL (mean 45.0 ng/mL) and 25(OH)D3 levels from 6.4 to 30.4 ng/mL 
(mean 15.0 ng/mL) (Supplemental Data, Table 1, that accompanies the 
article at http://www.degruyter.com/view/j/cclm.2016.54.issue-1/cclm-
2014-1249/cclm-2014-1249.xml?format=INT). All samples included in 
the present study had 3-epi-25(OH)D3 concentrations below the quan-
tification threshold of both LC-MS/MS methods ( < 5 ng/mL). In order to 
study the influence of the DBP concentration over 25(OH)D quantifica-
tion by the VIDAS® assay, serum samples from 25 pregnant women in 
their third trimester and 25 hemodialysis patients were determined for 
their DBP concentration using the Human Vitamin D BP Quantikine 
ELISA Kit (R&D Systems, Minneapolis, MN, USA).
Method comparison
The VIDAS® 25-OH Vitamin D Total assay was compared to other 
commercially available vitamin D assays according to the respec-
tive manufacturers’ recommendations. Measurements with VIDAS® 
Table 1: Precision performance of the VIDAS® 25-OH Vitamin D Total 
assay. 









Within-run precision Total precisiona
  SD   %CV SD   %CV
Pool 1   10.5  0.83   7.9   1.68   16
Pool 2   18.8  0.97   5.1   1.28   6.8
Pool 3   26  0.94   3.6   1.18   4.5
Pool 4   33.8  0.91   2.7   1.52   4.5
Pool 5   45.7  0.87   1.9   1.29   2.8
Pool 6   65.1  1.09   1.7   1.85   2.8
Pool 7   83.6  1.8   2.1   1.9   2.3
Pool 8   119.8  1.3   1.1   2.8   2.4
CV, coefficient of variation; SD, standard deviation. aBetween 
runs, between days, between calibrations, between lots, between 
instruments.
were performed at bioMérieux facilities (reagent lot 141016-0), 
Abbott Architect® (reagent lot 02513F000) at Laboratoires Bou-
vier Hache Vock (Roanne, France), IDS-iSYS® (reagent lot 1669) at 
Biomedlab 21 (Dijon, France), Roche Elecsys® (reagent lot 173852-
03) at Biomnis (Lyon, France) and DiaSorin Liaison XL (reagent lot 
130099) at Université de Liège (Liège, Belgium). All methods are 
routinely used in the respective laboratories and under external QC 
assessment.
Two different LC-MS/MS assays (at CHU Liège and LMU Münich 
sites) were also used as reference methodology for 25(OH)D quantifi-
cation. Both procedures are calibrated with NIST reference  materials; 
their respective principles are summarized in the Supplemental 
Material.
Statistics
The correlation of results between the various methods was ana-
lyzed using Passing-Bablok regression to determine proportional 
bias (slope) and constant bias (intercept). A Bland-Altman study of 
results was also carried out. The concordance correlation coefficient 
(CCC) was calculated. The CCC evaluates the degree to which pairs 
of observations fall on the 45° line through the origin. It includes 
a measurement of precision (Pearson’s correlation coefficient “r”) 
and accuracy (bias correction factor “Cb”). The Pearson’s correla-
tion coefficient measures how far each observation deviates from the 
best-fit line. The Cb measures how far the best-fit line deviates from 
the identity line. The CCC is calculated as: CCC = r × Cb. It can be inter-
preted as:  < 0.90 poor; 0.90–0.94 moderate; 0.95–1.00 good.
Results
Analytical performance of the VIDAS®  
25-OH Vitamin D Total assay
Precision
SD and CV were calculated for the VIDAS® 25-OH Vitamin 
D Total assay (Table 1). Repeatability represents the pre-
cision within-lot, -run and -instrument. Reproducibility 
includes all variability factors: precision between-runs, 
-days, -calibrations, -lots and -instruments.
SD for repeatability was in the 1 ng/mL range for all 
the different serum pools, yielding a CV from 7.9% at the 
lowest concentration of 25(OH)D tested (10.5 ng/mL) to 
1.1% at 120 ng/mL. Reproducibility SD varied from 1.5 to 
3.0 ng/mL, giving a CV range from 16.0% to 2.4%.
Linearity
A linearity study was performed using a high 25(OH)
D concentration serum pool serially diluted in a low 
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Figure 1:  Passing-Bablok and difference plots analysis of the two 
LC-MS/MS methods (A) and of 25(OH)D immunoassays compared 
with the consensus of LC-MS/MS methods (B).
For difference plots analysis, red line is mean bias, dashed blue line 
are upper and lower 95% limits of agreement.
concentration pool. Ten dilutions were prepared and 
 measured in duplicate. Analysis by weighted linear regres-
sion between observed and expected concentrations 
shows sustained linearity over the 7.1–126.2 ng/mL tested 
range with recovery  > 90% of expected values.
Limit of blank, limit of detection, and  
functional sensitivity
As per combined results on three reagent lots, the LoB 
of the VIDAS® 25-OH Vitamin D Total assay was deter-
mined as 6.2 ng/mL. Using the precision profile equation 
for low-level samples, LoD was calculated at 8.1 ng/mL. 
The deduced functional sensitivity (LoQ) (CV  < 20%) was 
5.9 ng/mL. By definition, LoQ cannot be lower than LoD; 
therefore LoQ was set at 8.1 ng/mL.
Cross-reactivity to vitamin D structural analogs
Assay specificity was evaluated by spiking samples with 
potential cross-reactant analytes and comparing the 
measurements with and without spiking. Mean cross 
reactivity to vitamin D3 was 3.7%; to 1,25-(OH)2D3 69.0%; to 
24,25-(OH)2D3 554.6% and to 3-epi-25(OH)D3 2.9%.
Serum/plasma comparison
A comparison of serum and plasma samples measure-
ments with the VIDAS® 25-OH Vitamin D Total assay was 
achieved using 60 matched-pairs. Passing-Bablok regres-
sion analysis shows excellent agreement between the two 
types of specimen at every level of analyte concentration 
(Supplemental Data, Figure 1).
Method comparison to LC-MS/MS and 
immunoassays
A total of 150 serum samples were tested in singulate 
by five automated immunoassays and two LC-MS/MS 
methods. Passing-Bablok regression indicates close 
agreement between the two LC-MS/MS assays for the 
entire cohort (Figure 1A), with a proportional bias (slope) 
of 1.04 (95% CI 1.00; 1.09) and a constant bias (Y-intercept) 
of −0.4 ng/mL (95% CI−1.57; 0.71). The CCC is 0.97. Due to 
result agreements between both LC-MS/MS methods, the 
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mean value from the two assays was used, as for all subse-
quent method comparisons with immunoassays.
The correlation statistics of commercial vitamin D 
immunoassays with mean LC-MS/MS results are summa-
rized in Table 2 and Figure 1B. In Passing-Bablok regres-
sion analysis, whereas the VIDAS®, Architect and Elecsys 
assays do not show proportional biases significantly dif-
ferent from 1 (as per the 95% IC values) with LC-MS/MS, 
Liaison and iSYS display a statistically significant mod-
erate negative slope. Constant bias (X-Intercept) for all 
immunoassays does not differ significantly from 0. The 
Bland-Altman plots show good overall agreement with 
LC-MS/MS for all the immunoassays, with a constant bias 
ranging from +2.4% (VIDAS®) to −12.5% (Liaison). While 
the CCC between LC-MS/MS and VIDAS®, Architect and 
Liaison reflects good overall correlation to the reference 
method ( > 0.90 with high accuracy [Cb of 0.97–1.00]), 
iSYS has a value slightly under the 0.90 cut-off value and 
Elecsys has a poor score (CCC = 0.82).
Influence of DBP on VIDAS® 25-OH  
Vitamin D Total assay accuracy
Variations in serum DBP concentration may disturb 
25(OH)D quantitation by immunoassays, especially in 
populations with altered DBP levels, due to physiological 
or pathological conditions [16]. The ability of the VIDAS® 
25-OH Vitamin D Total assay to measure 25(OH)D in the 
presence of various endogenous DBP levels was com-
pared with LC-MS/MS, which is not influenced by DBP 
variations. The study included serum samples from preg-
nant women in their third trimester (for high DBP con-
centration) and hemodialysis patients (for low levels of 
DBP). Passing-Bablok analysis shows no significant bias 
between VIDAS® and LC-MS/MS for pregnancy samples 
(Figure 2A), with an agreement between methods similar 
to that obtained previously (Table 2). For dialysis samples, 
VIDAS® results differ statistically from LC-MS/MS results 
with a slope of 0.51 (95% CI 0.43; 0.61) and a constant 
bias of 6.93 (95% CI 3.07; 9.38), clearly indicating that 
the VIDAS® assay under-recovers 25(OH)D as compared 
to LC-MS/MS in this population (Figure 2A). However, no 
correlation could be established between methods bias 
and DBP levels (r = −0.2, p > 0.1, not significant) when the 
(VIDAS – LC-MS/MS) difference was plotted against DBP 
concentration (Figure 2B).
Cross reactivity to 25(OH)D2 using natural 
25(OH)D2 samples
Serum samples from individuals supplemented with 
vitamin D2 were used to calculate 25(OH)D2 recovery, 
according to a previously published method [17]. Briefly, 
the regression equation comparing each immunoas-
say with LC-MS/MS samples was calculated for the D3 
serum cohort containing exclusively 25(OH)D3 (n = 150). 
The immunoassay 25(OH)D3 concentration was estimated 
by applying the D3 cohort regression equation to each 
vitamin D2 supplemented sample (n = 20). The 25(OH)D2 
levels were calculated by subtracting the 25(OH)D3 esti-
mated concentrations from the total 25(OH)D values. The 
25(OH)D2 cross-reactivity factor was obtained by divid-
ing the immunoassay 25(OH)D2 calculated concentration 
by the respective LC-MS/MS 25(OH)D2 value. Results are 
presented in Table 3. The VIDAS®, Architect and iSYS 
assays showed moderate under-recovery of 25(OH)D2 at 
82±20%, 76±24% and 86±31%, respectively [% mean±SD]. 
The Liaison assay slightly over-recovered 25(OH)D2 with 
a factor of 110±23%. The cross-reactivity to 25(OH)D2 
 recovery by the Elecsys assay was as low as mean value of 
46±20%. Only Liaison and iSYS assays show confidence 
intervals that include 100%.
Discussion
In response to the increased demand for vitamin D testing 
in the past decade, a wide array of commercial methods 
Table 2: Passing-Bablok regression statistics and concordance correlation analysis of immunoassays against the mean of the two  
LC-MS/MS methods. 
Methods   Slope   95% CI   Intercept, ng/mL   95% CI, ng/mL   CCC   95% CI   r, precision   Cb, accuracy
bioMérieux Vidas  1.01   [0.94–1.08]   0.22   [−2.05 to 1.97]   0.93   [0.90–0.95]   0.93   1.0
Abbott Architect   0.94   [0.88–1.01]   −0.17   [−1.84 to 1.38]   0.93   [0.90–0.95]   0.94   0.99
DiaSorin Liaison   0.90   [0.85–0.95]   −0.63   [−2.04 to 0.69]   0.92   [0.90–0.94]   0.95   0.97
Roche Elecsys   0.96   [0.87–1.05]   −1.75   [−4.19 to 0.60]   0.82   [0.77–0.87]   0.85   0.97
IDS iSYS   0.90   [0.84–0.97]   −0.42   [−2.20 to 1.10]   0.89   [0.85–0.91]   0.93   0.96
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Figure 2:  Passing-Bablok analysis of VIDAS vs. LC-MS/MS results in samples with altered DBP states (A) and difference plot analysis 
of (VIDAS – LC-MS/MS) as function of DBP concentration (B).
For difference plot analysis, linear regression is in green, with Pearson’s coefficient “r” and p-value “p”.
Table 3: Mean cross-reactivity to 25(OH)D2 of immunoassays 
assessed with natural serum samples. 
Methods   Mean 25(OH)D2 
cross-reactivity
  95% CI
bioMérieux Vidas   82%  (73%–91%)
Abbott Architect   76%  (65%–88%)
DiaSorin Liaison   110%  (99%–121%)
Roche Elecsys   46%  (37%–56%)
IDS iSYS   86%  (71%–100%)
has been made available to clinical laboratories and hos-
pitals. Vitamin D testing has now become a part of routine 
clinical practice due to fully automated, high throughput 
solutions. However, despite the extensive offer of vitamin 
D tests on the market, the technical challenge of measur-
ing such a difficult analyte, combined with the lack of an 
International Standard, has led to discrepancies between 
the analytical performances of the various methods, and 
moreover, a lack of correlation to the reference LC-MS/MS 
methods [18].
In this context, the present study aimed to evaluate the 
analytical and clinical characteristics of the new VIDAS® 
25-OH Vitamin D Total assay for routine determination of 
vitamin D status compared to the performance of other 
immunoassays and LC-MS/MS.
LC-MS/MS is currently considered the gold standard 
for 25(OH)D quantification, though in the past 10  years 
substantial disagreements have been documented 
between LC-MS/MS methods. DEQAS reports have more-
over clearly shown inter-laboratory CVs for LC-MS/MS 
methods that are comparable to immunoassays’ vari-
ability [19–21]. These discrepancies can be explained 
by the fact that LC-MS/MS is not a single “off the shelf” 
technique. Pre-analytical sample preparation (solvent 
extraction, chromatography for analyte separation), lab-
oratory personnel skills, accurate result analysis, includ-
ing interpretation of 3-epimer 25(OH)D concentration to 
the final measurement, can account for the lack of har-
monized results. Nevertheless, the availability of NIST 
reference materials and the vitamin D Standardization 
Program have helped bridge the gap in the standardi-
zation of LC-MS/MS methods. In the present study, two 
different LC-MS/MS methods were used at different loca-
tions, using distinct sample preparation and chromatog-
raphy processes, as well as different mass spectrometry 
instruments. Both methods were standardized to NIST 
reference material and one site (CHU Liège, Belgium) is 
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also part of the vitamin D Standardization Program. Both 
assays showed excellent agreement across the range of 
7.4–91.3 ng/mL (mean value of LC-MS/MS methods), and 
therefore the mean value of the two methods was used 
for comparison with immunoassays. This accounts for 
the efficiency of the standardization efforts that have 
been made in recent years to homogenize results among 
LC-MS/MS users.
In contrast, immunoassays exhibit variable perfor-
mance and disparate results as compared to LC-MS/MS 
measurements. Elecsys has a low concordance with 
LC-MS/MS, with a statistically significant  < 0.9 (as per 
95% CI) CCC. This low value is the consequence of a poor 
precision (r = 0.85) as illustrated by the large scattering of 
individual results, while the mean bias remains accept-
able. All four other immunoassays (VIDAS®, Architect, 
Liaison, iSYS) showed an acceptable agreement with 
consensus LC-MS/MS values (CCC  > 0.90 as per 95% CI), 
which reflects rather limited bias and acceptable preci-
sion. These data partially differ from other results pre-
viously published that have shown substantial biases 
between some of these immunoassays and LC-MS/MS. 
The specimen sampling may explain these differences, 
as no significant C3-epi-25(OH)D was detected in any 
sample tested in the present study, given that some 
assays are more sensitive to this metabolite than others. 
It is also worth indicating that some commercial assays 
have recently been re-standardized with reference mate-
rials, thereby bringing better accuracy with respect to 
LC-MS/MS methods.
One key element to ensure that an assay is fit for 
clinical use is to maintain consistency of measurement 
along its measuring range, which is bound at the low 
end by LoQ while the upper-limit is set by linear range 
determination. For the VIDAS® 25-OH Vitamin D Total 
assay, the measuring range was established as 8.1–126.0 
ng/mL. This interval encompasses commonly used 
clinical thresholds for vitamin D testing:  <  20 ng/mL 
(deficiency),  < 30  ng/mL (insufficiency) and goes up 
to  > 100 ng/mL. It is recommended to use biological var-
iations as a guide to assess the analytical performance 
of each assay [22, 23]. For vitamin D, within-subject var-
iation has been shown to reach 12% [24]. Stockl et  al. 
[25] proposed an acceptable CV of  < 10% for routine 
measurement purposes, emphasizing that the preci-
sion bias should be set at half this limit to routinely 
achieve the required quality. Therefore, using a target 
value of CV = 5%, the VIDAS® 25-OH Vitamin  D Total 
assay meets this requirement for within-run precision 
( repeatability) at thresholds of 20 ng/mL, 30 ng/mL and 
100 ng/mL (Table 1). Total precision (which includes 
variability between runs, calibrations, reagent lots and 
instruments) also falls under this cut-off, except for 
the 20 ng/mL level which is slightly over 6% precision. 
Taken together, these data demonstrate consistency in 
25(OH)D measurement, which is analytically accept-
able for samples spanning the entire assay range.
Another essential feature of a vitamin D assay is the 
detection of 25(OH)D2. As supplementation of patients 
with vitamin D2 is common in some parts of the world, the 
ability of an assay to accurately quantify 25(OH)D2 together 
with 25(OH)D3 is critical in the context of routine prac-
tice with limited information available on each patient’s 
potential supplementation regimen. However, estimating 
immunoassays’ cross-reactivity to 25(OH)D2 is a complex 
task, since only chromatographic methods are able to 
quantify both 25(OH)D forms separately. The use of 25(OH)
D2-spiked samples is irrelevant because recovery of exog-
enous 25(OH)D is inconsistent among immunoassays [26–
28]. Therefore, natural samples that contain endogenous 
25(OH)D2 should be studied. Cross-reactivity for 25(OH)D2 
was found to range from 46% (Roche) to 110% (Liaison). 
VIDAS®, Architect, iSYS and Liaison either slightly under- 
or over-recovered endogenous 25(OH)D2. These data differ 
from the results of previously published studies [17, 29] 
in which most immunoassays centered around 100% of 
cross-reactivity to 25(OH)D2. Shu et al. [30] observed that 
the relative amount of 25(OH)D2 in the tested samples 
can affect the results for cross-reactivity determination. 
Accordingly, in this study, we used serum samples with 
total 25(OH)D concentrations from 28 to 85 ng/mL and 
D2/D3 ratio of (0.7; 7). This broad range of 25(OH)D2 and 
25(OH)D3 relative amounts and the diverse D2/D3 ratio may 
explain observed discrepancies.
Previous studies have shown that the capacity of 
immunoassays to detect 25(OH)D could be hampered 
in samples from clinically defined populations, such as 
pregnant women, hemodialysis or intensive care patients, 
with a link between altered DBP levels and immunoassay 
poor performance [31]. In our study, however, we did not 
find a relationship between DBP concentration and devia-
tions of 25(OH)D measured with VIDAS® from LC-MS/MS 
results. VIDAS® performance for routine samples was not 
different from that for pregnancy samples, but VIDAS® 
consistently produced lower results for hemodialysis 
patients, with a Bland-Altman mean bias of 40% (data not 
shown). As this bias is not correlated to the DBP level, one 
explanation could be that dialysis samples suffer from 
matrix effects due to retained metabolites or elevated 
uremia that may interfere with 25(OH)D release from DBP 
and/or with immunoassay components, as previously 
postulated [16, 32].
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In conclusion, the VIDAS® 25-OH Vitamin D Total 
assay showed good analytical performance in terms of 
precision and reproducibility both at low and high 25(OH)
D concentrations. Results obtained with this new assay 
show excellent concordance to the reference LC-MS/MS 
method. Cross-reactivity to 25(OH)D2 is good and adapted 
to the use of the VIDAS® 25-OH Vitamin D Total assay in 
clinical routine.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Financial support: Etienne Cavalier is consultant for IDS 
and Diasorin and has received lecture fees from Abbott, 
IDS, DiaSorin and Roche. Michael Vogeser has received 
research funding from Institut Mérieux.
Employment or leadership: Emmanuel Moreau, Nadia Piga 
and Michael Hausmann are employees of bioMerieux Inc.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: 
266–81.
2. Lips P, van Schoor NM. The effect of vitamin D on bone 
and osteoporosis. Best Pract Res Clin Endocrinol Metab 
2011;25:585–91.
3. Prentice A, Schoenmakers I, Laskey MA, de Bono S, Ginty F, 
Goldberg GR. Nutrition and bone growth and development. Proc 
Nutr Soc 2006;65:348–60.
4. Autier P, Gandini S. Vitamin D supplementation and total 
 mortality: a meta-analysis of randomized controlled trials. 
Arch Intern Med 2007;167:1730–7.
5. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. 
Intake of vitamin D and risk of type 1 diabetes: a birth-cohort 
study. Lancet 2001;358:1500–3.
6. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, 
Wang TJ, et al. Vitamin D and musculoskeletal health, 
cardiovascular disease, autoimmunity and cancer: 
recommendations for clinical practice. Autoimmun Rev 
2010;9:709–15.
7. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, 
et al. Vitamin D effects on musculoskeletal health, immunity, 
autoimmunity, cardiovascular disease, cancer, fertility, preg-
nancy, dementia and mortality – a review of recent evidence. 
Autoimmun Rev 2013;12:976–89.
8. Bikle DD. Vitamin D metabolism, mechanism of action, and 
 clinical applications. Chem Biol 2014;21:319–29.
9. Phinney KW, Bedner M, Tai SS, Vamathevan VV, Sander LC, 
Sharpless KE, et al. Development and certification of a standard 
reference material for vitamin D metabolites in human serum. 
Anal Chem 2012;84:956–62.
10. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM. 
Vitamin D status as an international issue: national surveys and 
the problem of standardization. Scand J Clin Lab Invest Suppl 
2012;243:32–40.
11. Farrell CJ, Soldo J, McWhinney B, Bandodkar S, Herrmann M. 
Impact of assay design on test performance: lessons learned 
from 25-hydroxyvitamin D. Clin Chem Lab Med 2014;52:1579–87.
12. NCCLS. Interference testing in clinical chemistry, approved 
guideline EP07-A2, ISBN 1-56238-584-4.
13. NCCLS. Evaluation of precision performance of quantitative 
measurement methods, approved guideline, EP05-A2, ISBN 
1-56238-542-9.
14. NCCLS. Evaluation of the linearity of quantitative measurement 
procedures: a statistical approach, approved guideline EP06-A, 
ISBN 1-56238-498-8.
15. NCCLS. Protocols for determination of limits of detection 
and limits of quantitation, approved guideline EP17-A, ISBN 
1-56238-551-8.
16. Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. Accuracy of 
6 routine 25-hydroxyvitamin D assays: influence of vitamin D 
binding protein concentration. Clin Chem 2012;58:543–8.
17. Cavalier E, Rousselle O, Ferrante N, Carlisi A, Le Goff C, 
Souberbielle JC. Technical and clinical evaluation of the 
VITROS(R) immunodiagnostic products 25-OH vitamin D total 
assay – comparison with marketed automated immunoassays 
and a liquid chromatography-tandem mass spectrometry 
method. Clin Chem Lab Med 2013;51:1983–9.
18. Herrmann M. The measurement of 25-hydroxy vitamin D – an 
analytical challenge. Clin Chem Lab Med 2012;50:1873–5.
19. Binkley N, Sempos CT. Standardizing vitamin D assays: the way 
forward. J Bone Miner Res 2014;29:1709–14.
20. Grebe SK, Singh RJ. LC-MS/MS in the clinical laboratory – where 
to from here? Clin Biochem Rev 2011;32:5–31.
21. Singh RJ. Are clinical laboratories prepared for accurate testing 
of 25-hydroxy vitamin D? Clin Chem 2008;54:221–3.
22. Fraser CG, Petersen PH. Analytical performance characteristics 
should be judged against objective quality specifications. Clin 
Chem 1999;45:321–3.
23. Fuentes-Arderiu X, Miro-Balague J. State of the art instead of 
biological variation to set requirements for imprecision. Clin 
Chem 2000;46:1715–7.
24. Viljoen A, Singh DK, Farrington K, Twomey PJ. Analytical quality 
goals for 25-vitamin D based on biological variation. J Clin Lab 
Anal 2011;25:130–3.
25. Stockl D, Sluss PM, Thienpont LM. Specifications for true-
ness and precision of a reference measurement system for 
serum/plasma 25-hydroxyvitamin D analysis. Clin Chim Acta 
2009;408:8–13.
26. Carter GD, Jones JC, Berry JL. The anomalous behaviour of 
exogenous 25-hydroxyvitamin D in competitive binding assays. 
J Steroid Biochem Mol Biol 2007;103:480–2.
27. Horst RL. Exogenous versus endogenous recovery of 25-hydrox-
yvitamins D2 and D3 in human samples using high-performance 
liquid chromatography and the DiaSorin LIAISON Total-D Assay. 
J Steroid Biochem Mol Biol 2010;121:180–2.
Brought to you by | Université de Liège
Authenticated
Download Date | 8/21/15 4:03 PM
Moreau et al.: Performance characteristics of the VIDAS® 25-OH Vitamin D Total assay      9
28. Le Goff C, Peeters S, Crine Y, Lukas P, Souberbielle JC, Cavalier 
E. Evaluation of the cross-reactivity of 25-hydroxyvitamin D2 on 
seven commercial immunoassays on native samples. Clin Chem 
Lab Med 2012;50:2031–2.
29. Cavalier E, Wallace AM, Carlisi A, Chapelle JP, Delanaye P, 
Souberbielle JC. Cross-reactivity of 25-hydroxy vitamin D2 from 
different commercial immunoassays for 25-hydroxy vitamin D: 
an evaluation without spiked samples. Clin Chem Lab Med 
2011;49:555–8.
30. Shu I, Pina-Oviedo S, Quiroga-Garza G, Meng QH, Wang 
P.  Influence of vitamin D2 percentage on accuracy of 4 
commercial total 25-hydroxyvitamin D assays. Clin Chem 
2013;59:1273–5.
31. Cavalier E, Lukas P, Crine Y, Peeters S, Carlisi A, Le Goff C, et al. 
Evaluation of automated immunoassays for 25(OH)-vitamin D 
determination in different critical populations before and after 
standardization of the assays. Clin Chim Acta 2014;431:60–5.
32. Depreter B, Heijboer AC, Langlois MR. Accuracy of three 
 automated 25-hydroxyvitamin D assays in hemodialysis 
patients. Clin Chim Acta 2013;415:255–60.
Supplemental Material: The online version of this article 
(DOI: 10.1515/cclm-2014-1249) offers supplementary material, 
available to authorized users.
Brought to you by | Université de Liège
Authenticated
Download Date | 8/21/15 4:03 PM
